Novus Diagnostics
Novus Diagnostics are developing a revolutionary sample-to-answer sepsis diagnostic device.
- Company typePrivate
- Founded2020
- HeadquartersDublin, Ireland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Novus Diagnostics does
Novus Diagnostics are developing a revolutionary sample-to-answer sepsis diagnostic device that can rapidly detect and classify pathogens in whole blood.
Novus Diagnostics firmographics
Firmographics- Name
- Novus Diagnostics
- Legal name
- Novus Diagnostics Limited
- Website
- https://www.novus-dx.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Novus Diagnostics are developing a revolutionary sample-to-answer sepsis diagnostic device.
- Ownership category
- akta.pro rank
Novus Diagnostics industry classification
Industry- Product category
- In-Vitro Diagnostics / Point-of-Care Sepsis Diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)
Keywords
Where Novus Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- Ireland
- HQ region
- Europe
Offices1 record
Markets served
Novus Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- SepTec Diagnostic Platform: Revenue expected from sale of the SepTec rapid sepsis diagnostic platform and associated test consumables for point-of-care use in clinical settings.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Novus Diagnostics product offering
Product offeringCore offering
Novus Diagnostics develops SepTec™, a rapid point-of-care sepsis diagnostic platform using patented microfluidic electrochemical sensors to deliver 15-minute bedside results. The platform simultaneously confirms bloodstream infection and classifies the causative pathogen as gram positive, gram negative, or fungal, enabling clinicians to initiate targeted antimicrobial therapy in the critical early stages of triage. The company is pre-commercial, pursuing regulatory approval and validating the device in collaboration with two Dublin hospitals.
Product overview
Novus Diagnostics offers a single unified product platform called SepTec™, a rapid point-of-care diagnostic system for sepsis detection. The platform uses patented microfluidic electrochemical sensors and advanced diagnostic algorithms to deliver results in 15 minutes at the bedside, enabling clinicians to confirm infection and classify causative pathogens (gram positive, gram negative, or fungal) for immediate targeted treatment.
Differentiator
Problem solved
Functional benefit
Products and services
- SepTec™ A rapid point-of-care diagnostic platform for sepsis that delivers results in 15 minutes at the bedside using patented microfluidic electrochemical sensor technology. It enables simultaneous diagnosis of bloodstream infection and classification of the causative pathogen (gram positive, gram negative, or fungal), allowing clinicians to initiate targeted antimicrobial treatment during early triage. The product is intended for hospital emergency departments, ICUs, and clinical laboratory providers.
Quantifiable outcome
- 15-minute diagnosis vs 1-3 days for traditional methods
- +4 more outcomes
Companies that use Novus Diagnostics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Novus Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Novus Diagnostics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and moderate.
- FutureneurocoreResearch collaboration with Futureneuro invited to contribute 'Behind the Paper Blog' to Nature Research Device & Materials Engineering Community, showcasing SepTec technology development.
- Two Dublin HospitalscoreWorking in collaboration with two Dublin hospitals on validating the SepTec diagnostic device in clinical settings.
- MedTech InnovatormoderateAccepted onto 2020 MedTech Innovator Accelerator program (3% acceptance rate from 1,000+ applications) for mentorship and business support.
- EIT HealthmoderateSelected for EIT Health Headstart programme with access to mentoring, business support, €50k funding, and health innovation ecosystem network.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Novus Diagnostics competitors and assessment
Company assessmentDirect peers
- T2 Biosystems: Develops T2 Magnetic Resonance-based direct-from-blood diagnostics for sepsis and bloodstream infections, including the T2Bacteria and T2Candida panels. Direct competitor in rapid sepsis diagnostics, targeting similar hospital customers with faster alternative to blood culture.
- Accelerate Diagnostics: Offers the Accelerate Pheno system for rapid identification and antibiotic susceptibility testing directly from positive blood cultures. Comparable rapid infectious disease diagnostics focused on bloodstream infections with hospital microbiology labs and ICUs.
- Cytovale: Develops IntelliSep, a FDA-cleared rapid cellular biomarker test for sepsis diagnosis at the point of care in ED/ICU settings. Closely comparable in mission (faster sepsis triage) and target customer (hospital EDs/ICUs).
- Immunexpress: Commercializes SeptiCyte, a host-response gene-expression assay for sepsis diagnosis. Competes in the rapid sepsis diagnostic space, addressing the same clinical need for early differentiation of sepsis from SIRS.
Emerging players
- Inflammatix: Developer of host-response diagnostics (e.g., Inflammatix Acute Infection and Sepsis tests) using blood-based gene expression for rapid infection/sepsis assessment. Comparable in sepsis focus with a different (molecular) technology approach.
- Mölnlycke Health Code (bioMérieux adjunct — Qvella/Conidia): Qvella is developing rapid, culture-free pathogen ID from blood for sepsis diagnostics directly at the point of care. Early-stage peer with overlapping mission and POC bloodstream infection focus, though still pre-commercial.
Broad incumbents
- bioMérieux: Global leader in microbiology and infectious disease diagnostics, with BACT/ALERT blood culture systems and the BioFire BCID panel. Serves the same hospital microbiology and sepsis workflows that SepTec targets, with far broader portfolios.
- Becton Dickinson (BD): Major incumbent in blood culture and molecular diagnostics (BD MAX, BD Phoenix M50), serving the same hospital sepsis/bloodstream infection workflows. Broad IVD portfolio with the scale and distribution to dominate hospital adoption.
- Cepheid (Danaher): Maker of the GeneXpert molecular diagnostic platform with rapid infectious disease tests including bloodstream infection applications. Large installed hospital base and deep regulatory expertise make it a relevant broader incumbent.
- Roche Diagnostics: Global diagnostics leader offering blood culture, molecular, and immunoassay solutions for sepsis and infectious disease management across hospitals and reference labs. Relevant for benchmarking against large incumbents in the same clinical settings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Novus Diagnostics social profiles
Digital presenceNovus Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novus Diagnostics leadership team
Management profileNumber of profiles
Profiles4 records
Novus Diagnostics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novus Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novus Diagnostics
What does Novus Diagnostics do?
Novus Diagnostics develops SepTec™, a rapid point-of-care sepsis diagnostic platform using patented microfluidic electrochemical sensors to deliver 15-minute bedside results. The platform simultaneously confirms bloodstream infection and classifies the causative pathogen as gram positive, gram negative, or fungal, enabling clinicians to initiate targeted antimicrobial therapy in the critical early stages of triage. The company is pre-commercial, pursuing regulatory approval and validating the device in collaboration with two Dublin hospitals.
Is Novus Diagnostics a public or private company?
Novus Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Novus Diagnostics founded?
Novus Diagnostics was founded in 2020. It employs 11 to 50 people.
Where is Novus Diagnostics based?
Novus Diagnostics is headquartered in Dublin, Ireland, in the Europe region.
How does Novus Diagnostics make money?
One revenue line is on record: sepTec Diagnostic Platform.
Who are Novus Diagnostics's main competitors?
Direct peers on record are T2 Biosystems, Accelerate Diagnostics, Cytovale and Immunexpress. Emerging players are Inflammatix and Mölnlycke Health Code (bioMérieux adjunct — Qvella/Conidia). Broad incumbents are bioMérieux, Becton Dickinson (BD), Cepheid (Danaher) and Roche Diagnostics.
Does Novus Diagnostics have an API?
No public API is recorded for Novus Diagnostics.
What industry is Novus Diagnostics in?
Novus Diagnostics's product category is In-Vitro Diagnostics / Point-of-Care Sepsis Diagnostics. Its primary akta.pro industry code is HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis). Its NAICS code is 334510 and its SIC code is 3841.